ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i3.2764ppharm-2466Research ArticleОБЗОР ЛИТЕРАТУРЫREVIEWПотенциальное влияние некоторых факторов на течение псориаза у детейPotential Effects of Some Factors on Psoriasis Course in Childrenhttps://orcid.org/0000-0001-7649-5933ГубановаС. Г.GubanovaSvetlana G.

Губанова Светлана Геннадьевна - кандидат медицинских наук, ведущий научный сотрудник НИИ педиатрии и охраны здоровья детей НКЦ № 2.

119333, Москва, ул. Фотиевой, д. 10, стр. 1, тел.: +7 (499) 400-47-33

MD, PhD.

10, Fotievoi Str., building 1, Moscow, 113999

svetlanagub@gmail.comhttps://orcid.org/0000-0002-8232-8936АмбарчянЭ. Т.AmbarchyanEduard T.

Амбарчян Эдуард Тигранович - к.м.н.

Москва

MD, PhD.

Moscow

edo_amb@mail.ruhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Намазова-Баранова Лейла Сеймуровна - д.м.н., профессор, академик РАН.

Москва

MD, PhD, Professor, Academician of the RAS.

Moscow

leyla.s.namazova@gmail.comhttps://orcid.org/0000-0001-7398-0562ВишневаЕ. А.VishnevaElena A.

Вишнева Елена Александровна - д.м.н., профессор.

Москва

MD, PhD, Professor.

Moscow

vishneva.e@yandex.ruhttps://orcid.org/0000-0001-6158-9064ЗеленковаИ. В.ZelenkovaIrina V.

Зеленкова Ирина Валерьевна - к.м.н.

Москва

MD, PhD.

Moscow

izelen@mail.ruhttps://orcid.org/0000-0003-4962-6998ГанковскийВ. А.GankovskiyViktor A.

Ганковский Виктор Анатольевич - к.м.н.

Москва

MD, PhD.

Moscow

s.slon2012@yandex.ruhttps://orcid.org/0000-0003-4891-9959АлешенкоН. Л.AleshenkoNataliya L.

Алешенко Наталья Леонидовна

Москва

MD.

Moscow

nl.aleshenko@gmail.comhttps://orcid.org/0000-0002-8936-3590КайтуковаЕ. В.KaytukovaElena V.

Кайтукова Елена Владимировна - к.м.н.

Москва

MD, PhD.

Moscow

sunrise_ok@mail.ruhttps://orcid.org/0000-0003-3003-9398КузьминоваА. Д.KuzminovaAnastasiya D.

Кузьминова Анастасия Дмитриевна

Москва

MD.

Moscow

kuzminova_derma@mail.ruhttps://orcid.org/0000-0002-6760-3119ИванчиковВ. В.IvanchikovVladislav V.

Иванчиков Владислав Владимирович

Москва

MD.

Moscow

awdawd22@yandex.ruНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; РНИМУ им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian Federation202404072024213256262Copyright © Губанова С.Г., Амбарчян Э.Т., Намазова-Баранова Л.С., Вишнева Е.А., Зеленкова И.В., Ганковский В.А., Алешенко Н.Л., Кайтукова Е.В., Кузьминова А.Д., Иванчиков В.В., 20242024Губанова С.Г., Амбарчян Э.Т., Намазова-Баранова Л.С., Вишнева Е.А., Зеленкова И.В., Ганковский В.А., Алешенко Н.Л., Кайтукова Е.В., Кузьминова А.Д., Иванчиков В.В.Gubanova S.G., Ambarchyan E.T., Namazova-Baranova L.S., Vishneva E.A., Zelenkova I.V., Gankovskiy V.A., Aleshenko N.L., Kaytukova E.V., Kuzminova A.D., Ivanchikov V.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2466

Псориаз является вторым наиболее частым заболеванием кожи после атопического дерматита в детском возрасте. Существуют факторы, влияющие как на манифестацию, так и на обострение данного воспалительного кожного процесса. Ведущее значение в патогенезе псориаза в настоящее время отводится роли ключевых цитокинов. Тем не менее, триггерами псориаза также могут быть инфекционные заболевания.

В настоящее время подход к лечению псориаза у детей пересматривается в связи с появлением новых знаний об особенностях клинических проявлений и влиянии многочисленных коморбидных состояний на течение данной патологии. Оценка факторов риска, признаков и симптомов потенциальных сопутствующих заболеваний является важным компонентом ведения пациентов для построения прогностической модели прогрессирования основного заболевания и развития обострений, в том числе на фоне сопутствующих воспалительных процессов.

Psoriasis is the second most common skin disease after atopic dermatitis in childhood. There are factors affecting both the manifestation and aggravation of this inflammatory skin process. The leading role in the psoriasis pathogenesis is currently associated with key cytokines. However, infectious diseases could be the triggers for psoriasis.

Nowadays, the approach to psoriasis management in children has been revised due to emerging of new knowledge about the clinical manifestations and the role of numerous comorbid conditions in psoriasis course. Risk factors assessment, as well as evaluation of potential comorbidities signs and symptoms, is crucial part in patient management to create a prognostic model of the disease progression and the aggravation development (with underlying associated inflammatory processes included).

псориаздетикоморбидные состояниястрептококковая инфекцияpsoriasischildrencomorbid conditionsstreptococcal infectionОтсутствуетNot specifiedReferencesMenter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. https://doi.org/10.1016/j.jaad.2019.08.049Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201. https://doi.org/10.1016/j.jaad.2019.08.049Tkach VY, Voloshynovych MS, Girnyk GY, Kozak NV. Clinical features and the course of psoriasis in children. Dermatology Review. 2020;107(5):476–480. https://doi.org/10.5114/dr.2020.101677Tkach VY, Voloshynovych MS, Girnyk GY, Kozak NV. Clinical features and the course of psoriasis in children. Dermatology Review. 2020;107(5):476–480. https://doi.org/10.5114/dr.2020.101677Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121–129. https://doi.org/10.2147/PTT.S87650Pinson R, Sotoodian B, Fiorillo L. Psoriasis in children. Psoriasis (Auckl). 2016;6:121–129. https://doi.org/10.2147/PTT.S87650Paller AS, Singh R, Cloutier M, et al. Prevalence of psoriasis in children and adolescents in the United States: A claims-based analysis. J Drugs Dermatol. 2018;17(2):187–194.Paller AS, Singh R, Cloutier M, et al. Prevalence of psoriasis in children and adolescents in the United States: A claims-based analysis. J Drugs Dermatol. 2018;17(2):187–194.Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912. https://doi.org/10.1056/NEJMra041320Schön MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899–1912. https://doi.org/10.1056/NEJMra041320Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434–442. https://doi.org/10.1097/MOP.0000000000000517Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434–442. https://doi.org/10.1097/MOP.0000000000000517Dand N, Mahil SK, Capon F, et al. Psoriasis and Genetics. Acta Derm Venereol. 2020;100(3):adv00030. https://doi.org/10.2340/00015555-3384Dand N, Mahil SK, Capon F, et al. Psoriasis and Genetics. Acta Derm Venereol. 2020;100(3):adv00030. https://doi.org/10.2340/00015555-3384Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–820. https://doi.org/10.1093/hmg/6.5.813Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6(5):813–820. https://doi.org/10.1093/hmg/6.5.813Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLAC and ERAP1. Nat Genet. 2010;42(11):985–990. https://doi.org/10.1038/ng.694Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLAC and ERAP1. Nat Genet. 2010;42(11):985–990. https://doi.org/10.1038/ng.694Berki DM, Liu L, Choon SE, et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol. 2015;135(12):2964–2970. https://doi.org/10.1038/jid.2015.288Berki DM, Liu L, Choon SE, et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. J Invest Dermatol. 2015;135(12):2964–2970. https://doi.org/10.1038/jid.2015.288Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. https://doi.org/10.1016/j.coi.2017.07.007Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: A mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1–8. https://doi.org/10.1016/j.coi.2017.07.007Kamata M, Tada Y. Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis. Front Immunol. 2022;13:941071. https://doi.org/10.3389/fimmu.2022.941071Kamata M, Tada Y. Dendritic Cells and Macrophages in the Pathogenesis of Psoriasis. Front Immunol. 2022;13:941071. https://doi.org/10.3389/fimmu.2022.941071Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48(7):839–846. https://doi.org/10.1007/s00535-012-0678-9Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2013;48(7):839–846. https://doi.org/10.1007/s00535-012-0678-9Bronckers IMGJ, Paller AS, Van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs. 2015;17(5):373–384. https://doi.org/10.1007/s40272-015-0137-1Bronckers IMGJ, Paller AS, Van Geel MJ, et al. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Pediatr Drugs. 2015;17(5):373–384. https://doi.org/10.1007/s40272-015-0137-1Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573–574. https://doi.org/10.1001/jamadermatol.2014.324Becker L, Tom WL, Eshagh K, et al. Excess adiposity preceding pediatric psoriasis. JAMA Dermatol. 2014;150(5):573–574. https://doi.org/10.1001/jamadermatol.2014.324Амбарчян Э.Т., Намазова-Баранова Л.С., Мурашкин Н.Н. и др. Лептин и эпикардиальный жир: новые маркеры псориазау детей? Проспективное одномоментное исследование // Педиатрическая фармакология. — 2022. — Т. 19. — № 3. — С. 242–249. — https://doi.org/10.15690/pf.v19i3.2481Ambarchyan ET, Namazova-Baranova LS, Murashkin NN, et al. Leptin and Epicardial Fat: New Markers of Psoriasis in Children? Prospective Cross-Sectional Study. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2022;19(3):242–249. (In Russ). https://doi.org/10.15690/pf.v19i3.2481Намазова-Баранова Л.С., Амбарчян Э.Т., Иванчиков В.В. и др. Изменение толщины эпикардиальной жировой ткани у детей с псориазом на фоне биологической терапии: проспективное когортное исследование // Вопросы современной педиатрии. — 2023. — Т. 22. — № 5. — С. 406–414. — https://doi.org/10.15690/vsp.v22i5.2641Namazova-Baranova LS, Ambarchyan ET, Ivanchikov VV, et al. Changes in Epicardial Fatty Tissue Thickness in Pediatric Patients with Psoriasis and on Biological Therapy: Prospective Cohort Study. Voprosy sovremennoi pediatrii — Current Pediatrics. 2023;22(5):406–414. (In Russ). https://doi.org/10.15690/vsp.v22i5.2641Thomas J, Parimalam K. Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med Ther. 2016;7:25–28. https://doi.org/10.2147/PHMT.S75834Thomas J, Parimalam K. Treating pediatric plaque psoriasis: Challenges and solutions. Pediatric Health Med Ther. 2016;7:25–28. https://doi.org/10.2147/PHMT.S75834Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657. https://doi.org/10.1016/j.jaad.2011.11.948Kimball AB, Wu EQ, Guerin A, et al. Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol. 2012;67(4):651–657. https://doi.org/10.1016/j.jaad.2011.11.948Brihan I, Ianoși SL, Boda D, et al. Implications of self-esteem in the quality of life in patients with psoriasis. Exp Ther Med. 2020;20(2):202. https://doi.org/10.3892/etm.2020.9332Brihan I, Ianoși SL, Boda D, et al. Implications of self-esteem in the quality of life in patients with psoriasis. Exp Ther Med. 2020;20(2):202. https://doi.org/10.3892/etm.2020.9332van de Kerkhof PCM, Nestlé FO. Psoriasis. In: Dermatology. Bolognia JL, Schaffer JV, Cerroni L, eds. 4th edn. Philadelphia, PA: Elsevier; 2018. pp. 138–160.van de Kerkhof PCM, Nestlé FO. Psoriasis. In: Dermatology. Bolognia JL, Schaffer JV, Cerroni L, eds. 4th edn. Philadelphia, PA: Elsevier; 2018. pp. 138–160.Tollefson MM. Diagnosis and management of Psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–277. https://doi.org/10.1016/j.pcl.2013.11.003Tollefson MM. Diagnosis and management of Psoriasis in children. Pediatr Clin North Am. 2014;61(2):261–277. https://doi.org/10.1016/j.pcl.2013.11.003Хайрутдинов В.Р. Генетический паспорт больного псориазом // Вестник дерматологии и венерологии. — 2011. — № 4. — С. 14–19.Khairutdinov VR. Genetic profile of psoriasis patients. Vestnik Dermatologii i Venerologii. 2011;(4):14–19. (In Russ).Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511. https://doi.org/10.1128/cmr.13.3.470-511.2000Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev. 2000;13(3):470–511. https://doi.org/10.1128/cmr.13.3.470-511.2000Davison SC, Ballsdon A, Allen MH, et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol. 2001;10(4): 280–285. https://doi.org/10.1034/j.1600-0625.2001.100408.xDavison SC, Ballsdon A, Allen MH, et al. Early migration of cutaneous lymphocyte-associated antigen (CLA) positive T cells into evolving psoriatic plaques. Exp Dermatol. 2001;10(4): 280–285. https://doi.org/10.1034/j.1600-0625.2001.100408.xAllen HB, Jadeja S, Allawh RM, Goyal K. Psoriasis, chronic tonsillitis, and biofilms: Tonsillar pathologic findings supporting a microbial hypothesis. Ear Nose Throat J. 2018;97(3):79–82. https://doi.org/10.1177/014556131809700322Allen HB, Jadeja S, Allawh RM, Goyal K. Psoriasis, chronic tonsillitis, and biofilms: Tonsillar pathologic findings supporting a microbial hypothesis. Ear Nose Throat J. 2018;97(3):79–82. https://doi.org/10.1177/014556131809700322Watanabe R, Gehad A, Yang C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7(279):279ra39. https://doi.org/10.1126/scitranslmed.3010302Watanabe R, Gehad A, Yang C, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7(279):279ra39. https://doi.org/10.1126/scitranslmed.3010302De Jesús-Gil C, Ruiz-Romeu E, Ferran M, et al. CLA(+) T Cell Response to Microbes in Psoriasis. Front Immunol. 2018;9:1488. https://doi.org/10.3389/fimmu.2018.01488De Jesús-Gil C, Ruiz-Romeu E, Ferran M, et al. CLA(+) T Cell Response to Microbes in Psoriasis. Front Immunol. 2018;9:1488. https://doi.org/10.3389/fimmu.2018.01488Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol. 2012;188(10):5160–5165. https://doi.org/10.4049/jimmunol.1102834Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol. 2012;188(10):5160–5165. https://doi.org/10.4049/jimmunol.1102834Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: A systematic review. J Am Acad Dermatol. 2015;72(2):261–275. https://doi.org/10.1016/j.jaad.2014.10.013Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: A systematic review. J Am Acad Dermatol. 2015;72(2):261–275. https://doi.org/10.1016/j.jaad.2014.10.013Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: A randomized controlled trial. Acta Derm Venereol. 2017;97(3):340–345. https://doi.org/10.2340/00015555-2562Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Patient-reported outcomes and clinical response in patients with moderate-to-severe plaque psoriasis treated with tonsillectomy: A randomized controlled trial. Acta Derm Venereol. 2017;97(3):340–345. https://doi.org/10.2340/00015555-2562Ungprasert P, Wijarnpreecha K, Wetter DA. Periodontitis and risk of psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(5):857–862. https://doi.org/10.1111/jdv.14051Ungprasert P, Wijarnpreecha K, Wetter DA. Periodontitis and risk of psoriasis: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2017;31(5):857–862. https://doi.org/10.1111/jdv.14051Abdullah SN, Farmer EA, Spargo L, et al. Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. Anaerobe. 2013;23:102–108. https://doi.org/10.1016/j.anaer-obe.2013.07.001Abdullah SN, Farmer EA, Spargo L, et al. Porphyromonas gingivalis peptidylarginine deiminase substrate specificity. Anaerobe. 2013;23:102–108. https://doi.org/10.1016/j.anaer-obe.2013.07.001Zhang X, Gu H, Xie S, Su Y. Periodontitis in patients with psoriasis: A systematic review and meta-analysis. Oral Dis. 2022;28(1):33–43. https://doi.org/10.1111/odi.13617Zhang X, Gu H, Xie S, Su Y. Periodontitis in patients with psoriasis: A systematic review and meta-analysis. Oral Dis. 2022;28(1):33–43. https://doi.org/10.1111/odi.13617Taheri Sarvtin M, Shokohi T, Hajheydari Z. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol. 2014;53(12):e555– e560. https://doi.org/10.1111/ijd.12562Taheri Sarvtin M, Shokohi T, Hajheydari Z. Evaluation of candidal colonization and specific humoral responses against Candida albicans in patients with psoriasis. Int J Dermatol. 2014;53(12):e555– e560. https://doi.org/10.1111/ijd.12562Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31(4):455–463. https://doi.org/10.1016/j.clindermatol.2013.01.012Gaitanis G, Velegraki A, Mayser P, Bassukas ID. Skin diseases associated with Malassezia yeasts: facts and controversies. Clin Dermatol. 2013;31(4):455–463. https://doi.org/10.1016/j.clindermatol.2013.01.012Liu X, Cai Q, Yang H, et al. Distribution of Malassezia species on the skin of patients with psoriasis. J Mycol Med. 2021;31(2):101111. https://doi.org/10.1016/j.mycmed.2021.101111Liu X, Cai Q, Yang H, et al. Distribution of Malassezia species on the skin of patients with psoriasis. J Mycol Med. 2021;31(2):101111. https://doi.org/10.1016/j.mycmed.2021.101111Chang CH, Stein SL. Malassezia-associated skin diseases in the pediatric population. Pediatr Dermatol. 2024. https://doi.org/10.1111/pde.15603Chang CH, Stein SL. Malassezia-associated skin diseases in the pediatric population. Pediatr Dermatol. 2024. https://doi.org/10.1111/pde.15603Gomez-Moyano E, Crespo-Erchiga V, Martinez-Pilar L, et al. Do Malassezia species play a role in exacerbation of scalp psoriasis? J Mycol Med. 2014;24(2):87–92. https://doi.org/10.1016/j.mycmed.2013.10.007Gomez-Moyano E, Crespo-Erchiga V, Martinez-Pilar L, et al. Do Malassezia species play a role in exacerbation of scalp psoriasis? J Mycol Med. 2014;24(2):87–92. https://doi.org/10.1016/j.mycmed.2013.10.007Honnavar P, Chakrabarti A, Dogra S, et al. Phenotypic and molecular characterization of Malassezia japonica isolated from psoriasis vulgaris patients. J Med Microbiol. 2015;64(Pt 3):232–236. https://doi.org/10.1099/jmm.0.000011Honnavar P, Chakrabarti A, Dogra S, et al. Phenotypic and molecular characterization of Malassezia japonica isolated from psoriasis vulgaris patients. J Med Microbiol. 2015;64(Pt 3):232–236. https://doi.org/10.1099/jmm.0.000011Gemmer CM, Deangelis YM, Theelen B, et al. Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol. 2002;40(9):3350–3357. https://doi.org/10.1128/JCM.40.9.3350-3357.2002Gemmer CM, Deangelis YM, Theelen B, et al. Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol. 2002;40(9):3350–3357. https://doi.org/10.1128/JCM.40.9.3350-3357.2002Kanda N, Tani K, Enomoto U, et al. The skin fungus-induced Th1-and Th2-related cytokine, chemokine and prostaglandin E2 production in peripheral blood mononuclear cells from patients with atopic dermatitis and psoriasis vulgaris. Clin Exp Allergy. 2002;32(8):1243–1250. https://doi.org/10.1046/j.1365-2745.2002.01459.xKanda N, Tani K, Enomoto U, et al. The skin fungus-induced Th1-and Th2-related cytokine, chemokine and prostaglandin E2 production in peripheral blood mononuclear cells from patients with atopic dermatitis and psoriasis vulgaris. Clin Exp Allergy. 2002;32(8):1243–1250. https://doi.org/10.1046/j.1365-2745.2002.01459.xValli JL, Williamson A, Sharif S, et al. In vitro cytokine responses of peripheral blood mononuclear cells from healthy dogs to distemper virus, Malassezia and Toxocara. Vet Immunol Immunopathol. 2010;134(3-4):218–229. https://doi.org/10.1016/j.261vetimm.2009.09.023Valli JL, Williamson A, Sharif S, et al. In vitro cytokine responses of peripheral blood mononuclear cells from healthy dogs to distemper virus, Malassezia and Toxocara. Vet Immunol Immunopathol. 2010;134(3-4):218–229. https://doi.org/10.1016/j.261vetimm.2009.09.023Baroni A, Paoletti I, Ruocco E, et al. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasisaffected patients. J Cutan Pathol. 2004;31(1):35–42. https://doi.org/10.1046/j.0303-6987.2004.0135.xBaroni A, Paoletti I, Ruocco E, et al. Possible role of Malassezia furfur in psoriasis: modulation of TGF-beta1, integrin, and HSP70 expression in human keratinocytes and in the skin of psoriasisaffected patients. J Cutan Pathol. 2004;31(1):35–42. https://doi.org/10.1046/j.0303-6987.2004.0135.xFarr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet. 1985;2(8461):921–922. https://doi.org/10.1016/S0140-6736(85)90853-0Farr PM, Krause LB, Marks JM, Shuster S. Response of scalp psoriasis to oral ketoconazole. Lancet. 1985;2(8461):921–922. https://doi.org/10.1016/S0140-6736(85)90853-0Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of Genital Psoriasis: A Systematic Review. Dermatol Ther (Heidelb). 2018;8(4):509–525. https://doi.org/10.1007/s13555-018-0257-yBeck KM, Yang EJ, Sanchez IM, Liao W. Treatment of Genital Psoriasis: A Systematic Review. Dermatol Ther (Heidelb). 2018;8(4):509–525. https://doi.org/10.1007/s13555-018-0257-yFang H, Hou Y, Zhuang H, Wang C. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis. New Microbiol. 2022;45(2):130–137.Fang H, Hou Y, Zhuang H, Wang C. The effects of Malassezia in the activation of Interleukin (IL)-23/IL-17 axis in Psoriasis. New Microbiol. 2022;45(2):130–137.Pellicano R, Ribaldone DG, Fagoonee S, et al. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Med. 2016 58(4):304–137.Pellicano R, Ribaldone DG, Fagoonee S, et al. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Med. 2016 58(4):304–137.Al-Mendalawi M. Screening of Helicobacter pylori in patients with alopecia areata. Menoufia Med J. 2019;32(2):748. https://doi.org/10.4103/mmj.mmj_826_17Al-Mendalawi M. Screening of Helicobacter pylori in patients with alopecia areata. Menoufia Med J. 2019;32(2):748. https://doi.org/10.4103/mmj.mmj_826_17Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol. 2014;20(6):1510–1516. https://doi.org/10.3748/wjg.v20.i6.1510Magen E, Delgado JS. Helicobacter pylori and skin autoimmune diseases. World J Gastroenterol. 2014;20(6):1510–1516. https://doi.org/10.3748/wjg. v20.i6.1510Reid C, Griffiths CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020;100(3):adv00032. https://doi.org/10.2340/00015555-3386Reid C, Griffiths CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020;100(3):adv00032. https://doi.org/10.2340/00015555-3386Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020;80(4):341–352. https://doi.org/10.1007/s40265-020-01261-8Nogueira M, Puig L, Torres T. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020;80(4):341–352. https://doi.org/10.1007/s40265-020-01261-8Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023;37(1):35–55. https://doi.org/10.1007/s40259-022-00569-zJiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023;37(1):35–55. https://doi.org/10.1007/s40259-022-00569-z

The authors declare that there are no conflicts of interest present.